The effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease: A meta-analysis and systematic review

Heart and Lung: Journal of Acute and Critical Care

Volumn 46, Issue 2, 2017, Pages 120-128

  Fowdar, Kaushal ^a   Chen, Huan ^a   He, Zhiyi ^a   Zhang, Jiujin ^b   Zhong, Xiaoning ^a   Zhang, Jianquan ^a   Li, Meihua ^a   Bai, Jing ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b First People's Hospital of Yulin City   (China)

Author keywords

Chronic obstructive pulmonary disease; Effect; Exacerbation; Meta analysis; N acetylcysteine

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; SCAVENGER;

ABDOMINAL PAIN; ANTIBIOTIC THERAPY; ARTHRALGIA; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIARRHEA; DISEASE EXACERBATION; EPIGASTRIC DISCOMFORT; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HOSPITAL ADMISSION; HUMAN; INDIGESTION; INSPIRATORY CAPACITY; LOW DRUG DOSE; LUNG FUNCTION; MEDLINE; META ANALYSIS; MYALGIA; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN DISEASE; SYSTEMATIC REVIEW; TREATMENT DURATION; XEROSTOMIA; DRUG EFFECTS; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ACETYLCYSTEINE; ANTI-INFLAMMATORY AGENTS; FORCED EXPIRATORY VOLUME; FREE RADICAL SCAVENGERS; HUMANS; INSPIRATORY CAPACITY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 85009732651     PISSN: 01479563     EISSN: 15273288     Source Type: Journal    
DOI: 10.1016/j.hrtlng.2016.12.004     Document Type: Review

References (31)

1. 1 World Health Organization (WHO). The Global Burden of Disease. 2004 update, WHO, Geneva.
2. 2 Vestbo, J., Hurd, S.S., Agusti, A.G., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 187 (2013), 347–365, 10.1164/rccm.201204-0596PP.
3. 3 Sadowska, A.M., Verbraecken, J., Darquennes, K., et al. Role of N-acetylcysteine in the management of COPD. Int J Chron Obstruct Pulmon Dis 1 (2006), 425–434.
4. 4 Bachh, Arshad Altaf, Bhargava, Rakesh, Shah, Naveed Nazir, et al. Effect of oral N-acetylcysteine in COPD—a randomised controlled trial. JK Pract 14 (2007), 12–16.
5. 5 Pela, R., Calcagni, A.M., Subiaco, S., et al. N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration 66 (1999), 495–500.
6. 6 Zheng, J.P., Wen, F.Q., Bai, C.X., et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med 2 (2014), 187–194, 10.1016/s2213-2600(13)70286-8.
7. 7 Hansen, N.C., Skriver, A., Brorsen-Riis, L., et al. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. Respir Med 88 (1994), 531–535.
8. 8 Cazzola, M., Calzetta, L., Page, C., et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur Respir Rev 24 (2015), 451–461, 10.1183/16000617.00002215.
9. 9 Shen, Y., Cai, W., Lei, S., et al. Effect of high/low dose N-acetylcysteine on chronic obstructive pulmonary disease: a systematic review and meta-analysis. COPD 11 (2014), 351–358, 10.3109/15412555.2013.858315.
10. 10 Collins, P.F., Stratton, R.J., Elia, M., Nutritional support in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Am J Clin Nutr 95 (2012), 1385–1395, 10.3945/ajcn.111.023499.
11. 11 Jadad, A.R., Moore, R.A., Carroll, D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 17 (1996), 1–12.
12. 12 Celli, B.R., MacNee, W., Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23 (2004), 932–946.
13. 13 Burge, S., Wedzicha, J.A., COPD exacerbations: definitions and classifications. Eur Respir J Suppl 41 (2003), 46s–53s.
14. 14 Tse, H.N., Raiteri, L., Wong, K.Y., et al. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest 144 (2013), 106–118, 10.1378/chest.12-2357.
15. 15 McGavin, C.R., Macfarlane, J.T., Prescott, R.J., et al. Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. British Thoracic Society Research Committee. Thorax 40 (1985), 832–835.
16. 16 Grassi, C., Morandini, G.C., A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis. Eur J Clin Pharmacol 09 (1976), 393–396.
17. 17 Rasmussen, J.B., Glennow, C., Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis. Eur Respir J 1 (1988), 351–355.
18. 18 Schermer, T., Chavannes, N., Dekhuijzen, R., et al. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis. Respir Med 103 (2009), 542–551, 10.1016/j.rmed.2008.11.003.
19. 19 Decramer, M., Rutten-van Molken, M., Dekhuijzen, P.N., et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 365 (2005), 1552–1560, 10.1016/s0140-6736(05)66456-2.
20. 20 Stav, D., Raz, M., Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study. Chest 136 (2009), 381–386, 10.1378/chest.09-0421.
21. 21 De Backer, J., Vos, W., Van Holsbeke, C., et al. Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients. Int J Chron Obstruct Pulmon Dis 8 (2013), 569–579, 10.2147/copd.s49307.
22. 22 Zheng, J.P., Wen, F.Q., Bai, C.X., et al. High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON Study. COPD 10 (2013), 164–171, 10.3109/15412555.2012.732628.
23. 23 Dekhuijzen, P.N., Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J 23 (2004), 629–636.
24. 24 Kuleci, S., Hanta, I., Kocabas, A., et al. The effect of different treatment modalities on oxidative stress in COPD. Adv Ther 25 (2008), 710–717, 10.1007/s12325-008-0064-4.
25. 25 Li, J.H., He, H., Yu, W., et al. The effect of N-Acetylcysteine on oxidative stress and pulmonary function in elderly patients with COPD. J Yunyang Med Coll, 2008, 247–249.
26. 26 Kasielski, M., Nowak, D., Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respir Med 95 (2001), 448–456, 10.1053/rmed.2001.1066.
27. 27 De Benedetto, F., Aceto, A., Dragani, B., et al. Long-term oral n-acetylcysteine reduces exhaled hydrogen peroxide in stable COPD. Pulm Pharmacol Ther 18 (2005), 41–47, 10.1016/j.pupt.2004.09.030.
28. 28 Zuin, R., Palamidese, A., Negrin, R., et al. High-dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease. Clin Drug Investig 25 (2005), 401–408.
29. 29 van Overveld, F.J., Demkow, U., Gorecka, D., et al. New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine. J Physiol Pharmacol 56:suppl 4 (2005), 135–142.
30. 30 Riise, G.C., Larsson, S., Larsson, P., et al. The intrabronchial microbial flora in chronic bronchitis patients: a target for N-acetylcysteine therapy?. Eur Respir J 7 (1994), 94–101.
31. 31 Sadowska, A.M., Manuel, Y.K.B., De Backer, W.A., Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review. Pulm Pharmacol Ther 20 (2007), 9–22, 10.1016/j.pupt.2005.12.007.